-

Securities Fraud Investigation Into Stellantis N.V. (STLA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Stellantis N.V. (“Stellantis” or the “Company”) (NYSE: STLA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON STELLANTIS N.V. (STLA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On February 6, 2026, Stellantis disclosed that a “reset” of its business had “resulted in charges of approximately €22.2 billion … including cash payments of approximately €6.5 billion, which are expected to be paid over the next four years.” The Company explained that the reset and charges were due in significant part to the need to shift organizational priorities, stakeholder relationships, supply chains, execution, and quality control due to “an initial overestimation of pace of adoption of electrification in the regions.” Specifically, the Company cited “substantially reduced volume and profitability expectations for [battery-powered electric vehicles (“BEV”)] products.”

On this news, Stellantis’s stock price fell $2.26, or 23.7%, to close at $7.28 per share on February 6, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Stellantis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NYSE:STLA

Release Versions

Contacts

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

More News From The Law Offices of Frank R. Cruz

Securities Fraud Investigation Into Medpace Holdings, Inc. (MEDP) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON MEDPACE HOLDINGS, INC. (MEDP), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On February 9, 2026, Medpace released its fourth quarter 2025 f...

Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action...

Deadline Soon: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON INOVIO PHARMACEUTICALS, INC. (INO), CLICK HERE TO PARTIC...
Back to Newsroom